Detalhe da pesquisa
1.
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Blood
; 134(13): 1024-1036, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331917
2.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Br J Haematol
; 189(4): 650-660, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32180219
3.
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Blood
; 129(16): 2224-2232, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28167659
4.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Blood
; 126(6): 739-45, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26059948
5.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med
; 369(6): 507-16, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782157
6.
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.
Cancer Cell
; 41(1): 164-180.e8, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36563682
7.
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
J Pharmacol Exp Ther
; 337(3): 636-43, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21378206
8.
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Br J Haematol
; 170(1): 131-4, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25559624
9.
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Clin Cancer Res
; 12(2): 591-9, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16428505
10.
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Mol Cancer Ther
; 16(7): 1246-1256, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28428442
11.
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Clin Cancer Res
; 11(16): 6057-64, 2005 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16115951
12.
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.
Mol Cancer Ther
; 3(2): 179-86, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14985458
13.
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.
Oncotarget
; 6(21): 18693-706, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26155941
14.
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Nat Med
; 21(8): 922-6, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26193343
15.
Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.
Leuk Lymphoma
; 44(12): 2123-34, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14959858
16.
A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Clin Cancer Res
; 16(9): 2677-87, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20406832
17.
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Clin Cancer Res
; 16(2): 699-710, 2010 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20068101
18.
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Blood
; 105(12): 4759-66, 2005 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15728126